Loading…

Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo

Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2022-12, Vol.12, p.1074903
Main Authors: Li, Yali, Li, Sheng, Chen, Min, Xiao, Jialing, Fang, Hong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03
cites cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03
container_end_page
container_issue
container_start_page 1074903
container_title Frontiers in cellular and infection microbiology
container_volume 12
creator Li, Yali
Li, Sheng
Chen, Min
Xiao, Jialing
Fang, Hong
description Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against both and . A total of 20 strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against were evaluated the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The antifungal activity of PP alone and in combination with azoles and AmB against infections was evaluated by survival assay. The results revealed that PP individually was ineffective against (MIC>16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of , respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone ( = 0.04). In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against ; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of infection larvae, compared with they are alone. The and data show that PP could enhance the activity of POS against This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.
doi_str_mv 10.3389/fcimb.2022.1074903
format article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16</doaj_id><sourcerecordid>36569209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</originalsourceid><addsrcrecordid>eNpVkdtqGzEQhkVpaUKaF-hF0QvYHUm7WummUEwPgUAvmlyL0clV8EqLtDa4T9-NnYZENyPN8H-D-Aj5yGAthNKfo0ujXXPgfM1g6DSIN-SSc9GvuFbq7Yv7Bblu7QGWMwBXWrwnF0L2UnPQl2T8fcyhblObk6MhxuBmWiKdjvWQctqPdMKx4BwoZk-n0tCVjH_LbmlsMeU20009TnNxxbl9ozmUWOqIudGU6SHNtZySp8ehfCDvIu5auH6qV-T--7e7zc_V7a8fN5uvtyvXSTWvpBNWWe0tE2A7J1lEIT2GEHsQPgyDhNBry6xG8IPUGBQX2gsvoPPegrgiN2euL_hgpppGrEdTMJlTo9Stwbr8eBdMdEIBhp5LcB3Tg5WcdSi17ryWnsmF9eXMmvZ2DN6FPFfcvYK-nuT0x2zLwehBQSf7BcDPAFdLazXE5ywD8-jSnFyaR5fmyeUS-vRy63PkvznxD5Ccnxk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><source>PubMed Central</source><creator>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</creator><creatorcontrib>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</creatorcontrib><description>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against both and . A total of 20 strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against were evaluated the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The antifungal activity of PP alone and in combination with azoles and AmB against infections was evaluated by survival assay. The results revealed that PP individually was ineffective against (MIC&gt;16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of , respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone ( = 0.04). In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against ; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of infection larvae, compared with they are alone. The and data show that PP could enhance the activity of POS against This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</description><identifier>ISSN: 2235-2988</identifier><identifier>EISSN: 2235-2988</identifier><identifier>DOI: 10.3389/fcimb.2022.1074903</identifier><identifier>PMID: 36569209</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; antifungal ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; azoles ; Cellular and Infection Microbiology ; Cryptococcosis - drug therapy ; Cryptococcosis - microbiology ; Cryptococcus neoformans ; Fluconazole - pharmacology ; Fluconazole - therapeutic use ; Humans ; Itraconazole - pharmacology ; Itraconazole - therapeutic use ; Microbial Sensitivity Tests ; posaconazole ; pyrvinium pamoate ; synergistic effect ; Voriconazole - pharmacology</subject><ispartof>Frontiers in cellular and infection microbiology, 2022-12, Vol.12, p.1074903</ispartof><rights>Copyright © 2022 Li, Li, Chen, Xiao and Fang.</rights><rights>Copyright © 2022 Li, Li, Chen, Xiao and Fang 2022 Li, Li, Chen, Xiao and Fang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</citedby><cites>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780465/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780465/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36569209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yali</creatorcontrib><creatorcontrib>Li, Sheng</creatorcontrib><creatorcontrib>Chen, Min</creatorcontrib><creatorcontrib>Xiao, Jialing</creatorcontrib><creatorcontrib>Fang, Hong</creatorcontrib><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><title>Frontiers in cellular and infection microbiology</title><addtitle>Front Cell Infect Microbiol</addtitle><description>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against both and . A total of 20 strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against were evaluated the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The antifungal activity of PP alone and in combination with azoles and AmB against infections was evaluated by survival assay. The results revealed that PP individually was ineffective against (MIC&gt;16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of , respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone ( = 0.04). In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against ; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of infection larvae, compared with they are alone. The and data show that PP could enhance the activity of POS against This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</description><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>antifungal</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>azoles</subject><subject>Cellular and Infection Microbiology</subject><subject>Cryptococcosis - drug therapy</subject><subject>Cryptococcosis - microbiology</subject><subject>Cryptococcus neoformans</subject><subject>Fluconazole - pharmacology</subject><subject>Fluconazole - therapeutic use</subject><subject>Humans</subject><subject>Itraconazole - pharmacology</subject><subject>Itraconazole - therapeutic use</subject><subject>Microbial Sensitivity Tests</subject><subject>posaconazole</subject><subject>pyrvinium pamoate</subject><subject>synergistic effect</subject><subject>Voriconazole - pharmacology</subject><issn>2235-2988</issn><issn>2235-2988</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkdtqGzEQhkVpaUKaF-hF0QvYHUm7WummUEwPgUAvmlyL0clV8EqLtDa4T9-NnYZENyPN8H-D-Aj5yGAthNKfo0ujXXPgfM1g6DSIN-SSc9GvuFbq7Yv7Bblu7QGWMwBXWrwnF0L2UnPQl2T8fcyhblObk6MhxuBmWiKdjvWQctqPdMKx4BwoZk-n0tCVjH_LbmlsMeU20009TnNxxbl9ozmUWOqIudGU6SHNtZySp8ehfCDvIu5auH6qV-T--7e7zc_V7a8fN5uvtyvXSTWvpBNWWe0tE2A7J1lEIT2GEHsQPgyDhNBry6xG8IPUGBQX2gsvoPPegrgiN2euL_hgpppGrEdTMJlTo9Stwbr8eBdMdEIBhp5LcB3Tg5WcdSi17ryWnsmF9eXMmvZ2DN6FPFfcvYK-nuT0x2zLwehBQSf7BcDPAFdLazXE5ywD8-jSnFyaR5fmyeUS-vRy63PkvznxD5Ccnxk</recordid><startdate>20221209</startdate><enddate>20221209</enddate><creator>Li, Yali</creator><creator>Li, Sheng</creator><creator>Chen, Min</creator><creator>Xiao, Jialing</creator><creator>Fang, Hong</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221209</creationdate><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><author>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>antifungal</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>azoles</topic><topic>Cellular and Infection Microbiology</topic><topic>Cryptococcosis - drug therapy</topic><topic>Cryptococcosis - microbiology</topic><topic>Cryptococcus neoformans</topic><topic>Fluconazole - pharmacology</topic><topic>Fluconazole - therapeutic use</topic><topic>Humans</topic><topic>Itraconazole - pharmacology</topic><topic>Itraconazole - therapeutic use</topic><topic>Microbial Sensitivity Tests</topic><topic>posaconazole</topic><topic>pyrvinium pamoate</topic><topic>synergistic effect</topic><topic>Voriconazole - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yali</creatorcontrib><creatorcontrib>Li, Sheng</creatorcontrib><creatorcontrib>Chen, Min</creatorcontrib><creatorcontrib>Xiao, Jialing</creatorcontrib><creatorcontrib>Fang, Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in cellular and infection microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yali</au><au>Li, Sheng</au><au>Chen, Min</au><au>Xiao, Jialing</au><au>Fang, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</atitle><jtitle>Frontiers in cellular and infection microbiology</jtitle><addtitle>Front Cell Infect Microbiol</addtitle><date>2022-12-09</date><risdate>2022</risdate><volume>12</volume><spage>1074903</spage><pages>1074903-</pages><issn>2235-2988</issn><eissn>2235-2988</eissn><abstract>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against both and . A total of 20 strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against were evaluated the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The antifungal activity of PP alone and in combination with azoles and AmB against infections was evaluated by survival assay. The results revealed that PP individually was ineffective against (MIC&gt;16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of , respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone ( = 0.04). In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against ; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of infection larvae, compared with they are alone. The and data show that PP could enhance the activity of POS against This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36569209</pmid><doi>10.3389/fcimb.2022.1074903</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2235-2988
ispartof Frontiers in cellular and infection microbiology, 2022-12, Vol.12, p.1074903
issn 2235-2988
2235-2988
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16
source PubMed Central
subjects Amphotericin B - pharmacology
Amphotericin B - therapeutic use
antifungal
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
azoles
Cellular and Infection Microbiology
Cryptococcosis - drug therapy
Cryptococcosis - microbiology
Cryptococcus neoformans
Fluconazole - pharmacology
Fluconazole - therapeutic use
Humans
Itraconazole - pharmacology
Itraconazole - therapeutic use
Microbial Sensitivity Tests
posaconazole
pyrvinium pamoate
synergistic effect
Voriconazole - pharmacology
title Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A43%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergistic%20effect%20of%20pyrvinium%20pamoate%20and%20posaconazole%20against%20Cryptococcus%20neoformans%20in%20vitro%20and%20in%20vivo&rft.jtitle=Frontiers%20in%20cellular%20and%20infection%20microbiology&rft.au=Li,%20Yali&rft.date=2022-12-09&rft.volume=12&rft.spage=1074903&rft.pages=1074903-&rft.issn=2235-2988&rft.eissn=2235-2988&rft_id=info:doi/10.3389/fcimb.2022.1074903&rft_dat=%3Cpubmed_doaj_%3E36569209%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36569209&rfr_iscdi=true